Daniel C Rabe
机构: Massachusetts General Hospital, Harvard Medical School, Broad Institute
主页: researchgate.net
每年引用次数
引用次数
引用: 1,594
H-指数: 14
I10-指数 : 15
出版物: 51
Targeted Disruption of Heparan Sulfate Interaction with Hepatocyte and Vascular Endothelial Growth Factors Blocks Normal and Oncogenic Signaling
Fabiola Cecchi , Deborah Pajalunga , C. Andrew Fowler , Aykut Üren
Cancer Cell 22 ( 2) 250 -262
46
2012
Natural product inhibitors of hypoxia inducible factor-2a for the treatment of renal cell carcinoma
MM Lee , DC Rabe , TC Mckee , GM Woldemichael
EUROPEAN JOURNAL OF CANCER 103 E95 -E95
2018
Isolation of intact extracellular vesicles from cryopreserved samples.
Shannon N Tessier , Alona Muzikansky , Shannon L Stott , Eduardo Reátegui
PLOS ONE 16 ( 5)
2021
Tumor extracellular vesicles are required for tumor-associated macrophage programming
Daniel C Rabe , Felicia D Rustandy , Jiyoung Lee , Marsha Rich Rosner
bioRxiv 375022
2
2018
Targeting the HGF/Met signaling pathway in cancer therapy.
Fabiola Cecchi , Daniel C Rabe , Donald P Bottaro
Expert Opinion on Therapeutic Targets 16 ( 6) 553 -572
240
2012
Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype
Rebecca L Porter , Siyu Sun , Micayla N Flores , Emily Berzolla
The Journal of Clinical Investigation 132 ( 16)
4
2022
Abstract PR02: metastasis suppressors regulate the tumor microenvironment by blocking recruitment of pro-metastatic tumor-associated macrophages
Daniel C Rabe , Casey Frankenberger , Russell Bainer , Devipriya Sankarasharma
Cancer Research 76 ( 7_Supplement) PR02 -PR02
1
2016
Abstract A01: Metastasis suppressors regulate the tumor microenvironment by blocking recruitment of pro-metastatic tumor-associated macrophages
Daniel C Rabe , Casey Frankenberger , Russell Bainer , Devipriya Sankarasharma
Cancer Research 76 ( 7_Supplement) A01 -A01
2016
Abstract A43: Systemic tumor-stroma interactions are prognostic indicators of breast tumor invasiveness
Casey A Frankenberger , Russell O Bainer , Daniel C Rabe , Sadiq Saleh
Cancer Research 75 ( 1_Supplement) A43 -A43
2015
Triple-negative breast cancer displays a unique subset of macrophages dependent on CCL5 signaling
Daniel C Rabe , Casey Frankenberger , Russell Bainer , Yoav Gilad
Cancer Research 74 ( 19_Supplement) 1084 -1084
2014
The identification and development of selective natural product inhibitors of hypoxia inducible factor-2 alpha for the treatment of renal cell carcinoma
Molly M Lee , Daniel C Rabe , Tawnya C McKee , Girma M Woldemichael
MOLECULAR CANCER THERAPEUTICS 17 ( 1)
2018
Identification and characterization of natural product-based inhibitors of hypoxia inducible factor-2 alpha
Daniel C Rabe , Tawnya McKee , Girma M Woldemichael , James R Vasselli
Cancer Research 70 ( 8_Supplement) 773 -773
2010
Exosomes, microvesicles, and other extracellular vesicles—a Keystone Symposia report
Jennifer Cable , Kenneth W Witwer , Robert J Coffey , Aleksandar Milosavljevic
Annals of the New York Academy of Sciences 1523 ( 1) 24 -37
6
2023
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Manish A Shah , Zev A Wainberg , Daniel VT Catenacci , Howard S Hochster
PLoS ONE 8 ( 3) e54014
151
2013
Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients
Fabiola Cecchi , Yuan Liu , Robert C Gagnon , Howard Kallender
Molecular Cancer Therapeutics 8 ( 12_Supplement) B210 -B210
2
2009
Tumor extracellular vesicles regulate macrophage-driven metastasis through CCL5
Daniel C Rabe , Nykia D Walker , Felicia D Rustandy , Jessica Wallace
Cancers 13 ( 14) 3459 -3459
25
2021
Aryl‐Diazonium Salts Offer a Rapid and Cost‐Efficient Method to Functionalize Plastic Microfluidic Devices for Increased Immunoaffinity Capture
Daniel C Rabe , Uyen K Ho , Adarsh Choudhury , Jessica C Wallace
Advanced Materials Technologies 8 ( 16) 2300210 -2300210
2023
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Manish A Shah , Zev A Wainberg , Daniel VT Catenacci , Howard S Hochster
PloS one 17 ( 10) e0276211 -e0276211
1
2022